FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
FocalTherics (FOCL) will release its third-quarter 2026 financial results after market close on November 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FocalTherics (FOCL) will release its third-quarter 2026 financial results after market close on November 5, 2026. The results cover the quarter ended September 30, 2026. Chief Executive Officer Ryan Rhodes and Chief Financial Officer Ken Mobeck will conduct a conference call and webcast at 4:30 p.m. Eastern Time that day.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET
FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET
AUSTIN, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that it will release its financial results for the third quarter ended September 30, 2026, after market close on Thursday, November 5, 2026.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
| Date: | Thursday, November 5, 2026, at 4:30 p.m. Eastern Time |
| Domestic: | 1-833-419-0865 |
| International: | 1-785-838-9333 |
| Passcode: | FOCAL |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1776674&tp_key=37ee4700b1 |
About FocalTherics
A recognized leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Investor Contacts
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
